Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).Prana Biotechnology Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology.